↓ Skip to main content

Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors

Overview of attention for article published in Clinical Cancer Research, January 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
9 news outlets
blogs
2 blogs
twitter
120 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
49 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors
Published in
Clinical Cancer Research, January 2022
DOI 10.1158/1078-0432.ccr-21-2275
Pubmed ID
Authors

Adam C. Palmer, Benjamin Izar, Haeun Hwangbo, Peter K. Sorger

Twitter Demographics

The data shown below were collected from the profiles of 120 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 49 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 37%
Other 10 20%
Student > Doctoral Student 3 6%
Student > Bachelor 2 4%
Professor 1 2%
Other 3 6%
Unknown 12 24%
Readers by discipline Count As %
Medicine and Dentistry 11 22%
Biochemistry, Genetics and Molecular Biology 5 10%
Engineering 4 8%
Immunology and Microbiology 4 8%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Other 8 16%
Unknown 14 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 139. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 June 2022.
All research outputs
#223,155
of 21,429,365 outputs
Outputs from Clinical Cancer Research
#90
of 12,198 outputs
Outputs of similar age
#6,545
of 387,327 outputs
Outputs of similar age from Clinical Cancer Research
#8
of 137 outputs
Altmetric has tracked 21,429,365 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,198 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 387,327 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 137 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.